EGFR and non-small cell lung carcinoma: Given that several trials have found that bevacizumab in combination with an EGFR-TKI might provide additional clinical benefits in NSCLC patients with activating EGFR mutations [28,29], a randomized phase Ib/III study (RELAY) to investigate the safety and efficacy of the combined use of ramucirumab and erlotinib in the first-line setting for patients with stage IV NSCLC positive for EGFR mutations is also now underway [30].